Revolution Medicines (NASDAQ:RVMD) Sets New 12-Month High - Should You Buy?

Revolution Medicines (NASDAQ:RVMD) Sets New 12-Month High - Should You Buy?

Revolution Medicines (NASDAQ:RVMD) Hits New 1-Year High - Still a Buy?

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration

SAN CARLOS, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Aug 10, 2026-

BeOne and Revolution Medicines partner for oncology therapies

The deal includes joint studies combining BeOne’s cancer pipeline assets with four clinical-stage RAS(ON) inhibitors from Revolution Medicines, alongside a regional rights agreement for select Asian markets. The The post BeOne and Revolution Medicines partner for oncology therapies appeared first on Pharmaceutical Business review.

RevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 win

Plus news about Avere Therapeutics, Novo Nordisk, Sobi, Innate Pharma, Oculis, Innovent Biologics and Daiichi Sankyo. 🌏 BeOne gets rights to RevMed drugs in 'select Asian markets': The deal includes Revolution Medicines' four clinical RAS ...